FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2018780010> ?p ?o ?g. }

• W2018780010 endingPage "354" @default.
• W2018780010 startingPage "347" @default.
• W2018780010 abstract "To investigate the efficacy and safety of donepezil in a subgroup of patients with Alzheimer's disease (AD) of moderate severity from a previous trial.Two hundred and seven patients with moderate AD (standardized Mini-Mental State Examination [sMMSE] score 10-17) were randomized to treatment in this 24-week, double-blind, placebo-controlled trial. Patents received either donepezil, 5 mg/day for the first 28 days and 10 mg/day thereafter according to the clinician's judgement (n = 102), or placebo (n = 105). The primary outcome measure was the Clinician's Interview-Based Impression of Change with caregiver input (CIBIC-plus) at week 24 using a last observation carried forward (LOCF) analysis.Baseline patient demographics were similar between treatment groups. Mean age was 74.3 years (range 48-92). Least-squares (LS) mean sMMSE scores at baseline were 13.6 +/- 0.3 for the donepezil group and 13.9 +/- 0.3 for the placebo group. LS mean CIBIC-plus scores for donepezil-treated patients were improved from, or close to, baseline severity at all visits, and were significantly different from placebo at weeks 8, 12, 18, and 24 (week 24 LOCF mean difference = 0.53, p = 0.0003). LS mean change from baseline scores on the sMMSE and Severe Impairment Battery (SIB) for the donepezil group improved throughout the study, and were significantly different from placebo at each visit for the sMMSE (week 24 LOCF mean difference = 2.06, p = 0.0002) and from week 8 for the SIB (week 24 LOCF mean difference = -4.44, p = 0.0026). LS mean change scores on the Disability Assessment for Dementia remained at or above baseline levels throughout the study for the donepezil group, while the placebo group showed a steady decline; treatment differences were significant at each visit (week 24 LOCF mean difference = -9.25, p < 0.0001). LS mean change scores on the Neuropsychiatric Inventory 12-item total improved throughout the study for the donepezil group and were significantly different from placebo at weeks 4 and 24 (week 24 LOCF mean difference = 5.92, p = 0.0022). Eighty-one per cent of donepezil-treated and 89% of placebo-treated patients completed the trial, with 9% and 5%, respectively, discontinuing due to adverse events (AEs). Eighty-two per cent of donepezil-treated and 80% of placebo-treated patients experienced AEs, the majority of which were rated mild in severity and, in general, were similar between treatment groups.The significant treatment responses observed with donepezil in these patients reinforce the findings from earlier studies that show donepezil to have important benefits, compared wih placebo, across functional, cognitive, and behavioral symptoms, with good tolerability, in patients with AD of moderate severity." @default.
• W2018780010 created "2016-06-24" @default.
• W2018780010 creator A5004164730 @default.
• W2018780010 creator A5004968642 @default.
• W2018780010 creator A5020043337 @default.
• W2018780010 creator A5040711752 @default.
• W2018780010 creator A5049484291 @default.
• W2018780010 creator A5091826890 @default.
• W2018780010 date "2002-01-01" @default.
• W2018780010 modified "2023-10-02" @default.
• W2018780010 title "Functional, Cognitive and Behavioral Effects of Donepezil in Patients with Moderate Alzheimer's Disease" @default.
• W2018780010 cites W1164896577 @default.
• W2018780010 cites W1975975999 @default.
• W2018780010 cites W1978130969 @default.
• W2018780010 cites W1985528178 @default.
• W2018780010 cites W1997886955 @default.
• W2018780010 cites W2045923955 @default.
• W2018780010 cites W2047095305 @default.
• W2018780010 cites W2055727638 @default.
• W2018780010 cites W2057679568 @default.
• W2018780010 cites W2064649894 @default.
• W2018780010 cites W2081285591 @default.
• W2018780010 cites W2081342992 @default.
• W2018780010 cites W2093581851 @default.
• W2018780010 cites W2102343148 @default.
• W2018780010 cites W2111963393 @default.
• W2018780010 cites W2117134611 @default.
• W2018780010 cites W2122692162 @default.
• W2018780010 cites W2128529067 @default.
• W2018780010 cites W2137103253 @default.
• W2018780010 cites W2156220037 @default.
• W2018780010 cites W2775750683 @default.
• W2018780010 cites W398009941 @default.
• W2018780010 cites W4292528167 @default.
• W2018780010 cites W4379093136 @default.
• W2018780010 doi "https://doi.org/10.1185/030079902125001029" @default.
• W2018780010 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12442882" @default.
• W2018780010 hasPublicationYear "2002" @default.
• W2018780010 type Work @default.
• W2018780010 sameAs 2018780010 @default.
• W2018780010 citedByCount "72" @default.
• W2018780010 countsByYear W20187800102012 @default.
• W2018780010 countsByYear W20187800102013 @default.
• W2018780010 countsByYear W20187800102014 @default.
• W2018780010 countsByYear W20187800102016 @default.
• W2018780010 countsByYear W20187800102017 @default.
• W2018780010 countsByYear W20187800102018 @default.
• W2018780010 countsByYear W20187800102019 @default.
• W2018780010 countsByYear W20187800102020 @default.
• W2018780010 countsByYear W20187800102022 @default.
• W2018780010 countsByYear W20187800102023 @default.
• W2018780010 crossrefType "journal-article" @default.
• W2018780010 hasAuthorship W2018780010A5004164730 @default.
• W2018780010 hasAuthorship W2018780010A5004968642 @default.
• W2018780010 hasAuthorship W2018780010A5020043337 @default.
• W2018780010 hasAuthorship W2018780010A5040711752 @default.
• W2018780010 hasAuthorship W2018780010A5049484291 @default.
• W2018780010 hasAuthorship W2018780010A5091826890 @default.
• W2018780010 hasConcept C126322002 @default.
• W2018780010 hasConcept C142724271 @default.
• W2018780010 hasConcept C159110408 @default.
• W2018780010 hasConcept C187960798 @default.
• W2018780010 hasConcept C204787440 @default.
• W2018780010 hasConcept C27081682 @default.
• W2018780010 hasConcept C2779134260 @default.
• W2018780010 hasConcept C2779483572 @default.
• W2018780010 hasConcept C2779951463 @default.
• W2018780010 hasConcept C2780904820 @default.
• W2018780010 hasConcept C44249647 @default.
• W2018780010 hasConcept C502032728 @default.
• W2018780010 hasConcept C71924100 @default.
• W2018780010 hasConceptScore W2018780010C126322002 @default.
• W2018780010 hasConceptScore W2018780010C142724271 @default.
• W2018780010 hasConceptScore W2018780010C159110408 @default.
• W2018780010 hasConceptScore W2018780010C187960798 @default.
• W2018780010 hasConceptScore W2018780010C204787440 @default.
• W2018780010 hasConceptScore W2018780010C27081682 @default.
• W2018780010 hasConceptScore W2018780010C2779134260 @default.
• W2018780010 hasConceptScore W2018780010C2779483572 @default.
• W2018780010 hasConceptScore W2018780010C2779951463 @default.
• W2018780010 hasConceptScore W2018780010C2780904820 @default.
• W2018780010 hasConceptScore W2018780010C44249647 @default.
• W2018780010 hasConceptScore W2018780010C502032728 @default.
• W2018780010 hasConceptScore W2018780010C71924100 @default.
• W2018780010 hasIssue "6" @default.
• W2018780010 hasLocation W20187800101 @default.
• W2018780010 hasLocation W20187800102 @default.
• W2018780010 hasOpenAccess W2018780010 @default.
• W2018780010 hasPrimaryLocation W20187800101 @default.
• W2018780010 hasRelatedWork W1948364294 @default.
• W2018780010 hasRelatedWork W1989703975 @default.
• W2018780010 hasRelatedWork W1997886955 @default.
• W2018780010 hasRelatedWork W2011091925 @default.
• W2018780010 hasRelatedWork W2028881255 @default.
• W2018780010 hasRelatedWork W2124088010 @default.
• W2018780010 hasRelatedWork W2136332296 @default.
• W2018780010 hasRelatedWork W2584314249 @default.
• W2018780010 hasRelatedWork W2981304007 @default.

• next